Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Oct;58(10):1265-1279.
doi: 10.1007/s40262-019-00775-z.

Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review

Affiliations
Review

Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review

Wonkyung Byon et al. Clin Pharmacokinet. 2019 Oct.

Abstract

Apixaban is an oral, direct factor Xa inhibitor that inhibits both free and clot-bound factor Xa, and has been approved for clinical use in several thromboembolic disorders, including reduction of stroke risk in non-valvular atrial fibrillation, thromboprophylaxis following hip or knee replacement surgery, the treatment of deep vein thrombosis or pulmonary embolism, and prevention of recurrent deep vein thrombosis and pulmonary embolism. The absolute oral bioavailability of apixaban is ~ 50%. Food does not have a clinically meaningful impact on the bioavailability. Apixaban exposure increases dose proportionally for oral doses up to 10 mg. Apixaban is rapidly absorbed, with maximum concentration occurring 3-4 h after oral administration, and has a half-life of approximately 12 h. Elimination occurs via multiple pathways including metabolism, biliary excretion, and direct intestinal excretion, with approximately 27% of total apixaban clearance occurring via renal excretion. The pharmacokinetics of apixaban are consistent across a broad range of patients, and apixaban has limited clinically relevant interactions with most commonly prescribed medications, allowing for fixed dosages without the need for therapeutic drug monitoring. The pharmacodynamic effect of apixaban is closely correlated with apixaban plasma concentration. This review provides a summary of the pharmacokinetic, pharmacodynamic, biopharmaceutical, and drug-drug interaction profiles of apixaban. Additionally, the population-pharmacokinetic analyses of apixaban in both healthy subjects and in the target patient populations are discussed.

PubMed Disclaimer

Conflict of interest statement

Wonkyung Byon and Rebecca A. Boyd are current or former employees of Pfizer, Inc., and own stock/stock options. Samira Garonzik is an employee of Bristol-Myers Squibb. Charles E. Frost is an employee of, owns stock/stock options in, has received travel support and payment for lectures from, and is an inventor on patents with Bristol-Myers Squibb.

Figures

Fig. 1
Fig. 1
Chemical structure of apixaban
Fig. 2
Fig. 2
Absorption, distribution, metabolism, and elimination of apixaban [, , –19]. *Data from subjects following oral administration without bile collection. CYP cytochrome P450, Vss volume of distribution at steady state
Fig. 3
Fig. 3
Mean (+ standard deviation) plasma apixaban concentration vs. time profiles on days 1 and 7 [21]. Reproduced with permission from Frost et al. Br J Clin Pharmacol. 2013;76:776–86
Fig. 4
Fig. 4
Effect of intrinsic factors on the pharmacokinetics of apixaban [4]. *Subjects with end-stage renal disease (ESRD) treated with intermittent hemodialysis; reported pharmacokinetic (PK) findings are following a single dose of apixaban post-hemodialysis. Creatinine clearance (CrCl) > 80 mL/min. Severe, moderate, mild, and normal reflect CrCl of 15 mL/min, 40 mL/min, 65 mL/min, and 100 mL/min based on regression analyses. AUC area under the plasma concentration–time curve, CI confidence interval, Cmax maximum plasma concentration. Reproduced with permission from Eliquis (apixaban) US prescribing information
Fig. 5
Fig. 5
Effect of co-administered drugs on the pharmacokinetics of apixaban [4]. AUC area under the plasma concentration–time curve from time zero extrapolated to infinity, CI confidence interval, Cmax maximum plasma concentration, CYP3A4 cytochrome P450 3A4, P-gp P-glycoprotein, PK pharmacokinetics. Reproduced with permission from Eliquis (apixaban) US prescribing information
Fig. 6
Fig. 6
Scatter plots of a international normalized ratio (INR), b activated partial thromboplastin time (aPTT), c modified prothrombin time (mPT), and d, e anti-Xa activity vs. apixaban plasma concentration [35]. Reproduced with permission from Yamahira et al. Int J Clin Pharmacol Ther. 2014;52:564–73

References

    1. Bristol-Myers Squibb. Coumadin (wafarin sodium) prescribing information. 2017. http://packageinserts.bms.com/pi/pi_coumadin.pdf. Accessed 2 Feb 2018.
    1. Lip GYH, Banerjee A, Boriani G, Chiang CE, Fargo R, Freedman B, et al. Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. Chest. 2018;154(5):1121–1201. doi: 10.1016/j.chest.2018.07.040. - DOI - PubMed
    1. Bristol-Myers Squibb, Pfizer EEIG. EU summary of product characteristics: Eliquis (apixaban tablets). 2018. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Info.... Accessed 8 Apr 2019.
    1. Bristol-Myers Squibb Company PI. Eliquis (apixaban) prescribing information. 2018. http://packageinserts.bms.com/pi/pi_eliquis.pdf. Accessed 14 Jun 2018.
    1. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek E, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–992. doi: 10.1056/NEJMoa1107039. - DOI - PubMed

Publication types